Kieuhoa Vo, MD, MAS
Associate Professor
Pediatrics
School of Medicine

Education & Training

Show all (5) Hide

• M.A.S., Clinical Research University of California, San Francisco 2015
• Pediatric Oncology/Hematology Fellowship University of California, San Francisco 2015
• Pediatric Residency Nationwide Children's Hospital 2011
• M.D. Indiana University School of Medicine 2008
• B.S., Biological Sciences University of Notre Dame 2004

Publications (24)

Top publication keywords:
3-IodobenzylguanidinePharmacogeneticsTransplantation, AutologousThrombotic MicroangiopathiesBiological ProductsMenstruation DisturbancesNeoplasm Recurrence, LocalTransplantation ConditioningPelvic NeoplasmsMenstruationThoracic NeoplasmsSarcoma, EwingNeuroblastomaBlood Coagulation Disorders, InheritedNeoplasm Micrometastasis

• Abstract 1759: Integrative longitudinal genomic analysis of therapy-resistant and metastatic pediatric cancers.
  Cancer Research 2024 Henry J. Martell, Avanthi T. Shah, Alex G. Lee, Stanley G. Leung, Soo-Jin Cho, María Pons Ventura, Ana Golla, Amanda E. Marinoff, Elizabeth P. Young, Bogdan Tanasa, Inge Behroozfard, Heng-Yi Liu, Aviv…
• Pediatric neuroblastoma with intraspinal extension: the role of surgical management.
  Journal of neurosurgery. Pediatrics 2023 Chang D, Oh T, Roland JL, Matthay KK, Vo KT, Edwards CS, Sun PP, Auguste KI, Gupta N
• Norepinephrine transporter and vesicular monoamine transporter 2 tumor expression as a predictor of response to 131 I-MIBG in patients with relapsed/refractory neuroblastoma.
  Pediatric blood & cancer 2023 Batra V, Gikandi A, Pawel B, Martinez D, Granger MM, Marachelian A, Park JR, Maris JM, Vo KT, Matthay KK, DuBois SG
• Venetoclax in combination with chemotherapy as treatment for pediatric advanced hematologic malignancies.
  Pediatric blood & cancer 2023 Marinoff AE, Aaronson K, Agrawal AK, Braun BS, Golden C, Huang BJ, Michlitsch J, Southworth E, Thrall A, Vo KT, Stieglitz E
• Lorlatinib with or without chemotherapy in ALK-driven refractory/relapsed neuroblastoma: phase 1 trial results.
  Nature medicine 2023 Goldsmith KC, Park JR, Kayser K, Malvar J, Chi YY, Groshen SG, Villablanca JG, Krytska K, Lai LM, Acharya PT, Goodarzian F, Pawel B, Shimada H, Ghazarian S, States L, Marshall L, Chesler L, Granger M,…

Show all (19 more) Hide

• Incorporating Radiomics into Machine Learning Models to Predict Outcomes of Neuroblastoma.
  Journal of digital imaging 2022 Liu G, Poon M, Zapala MA, Temple WC, Vo KT, Matthay KK, Mitra D, Seo Y
• Pattern and predictors of sites of relapse in neuroblastoma: A report from the International Neuroblastoma Risk Group (INRG) project.
  Pediatric blood & cancer 2022 Vo KT, DuBois SG, Neuhaus J, Braunstein SE, Weil BR, Naranjo A, Irtan S, Balaguer J, Matthay KK
• A Comprehensive Circulating Tumor DNA Assay for Detection of Translocation and Copy-Number Changes in Pediatric Sarcomas.
  Molecular cancer therapeutics 2021 Shah AT, Azad TD, Breese MR, Chabon JJ, Hamilton EG, Straessler K, Kurtz DM, Leung SG, Spillinger A, Liu HY, Behroozfard IH, Wittber FM, Hazard FK, Cho SJ, Daldrup-Link HE, Vo KT, Rangaswami A, …
• Randomized Phase II Trial of MIBG Versus MIBG, Vincristine, and Irinotecan Versus MIBG and Vorinostat for Patients With Relapsed or Refractory Neuroblastoma: A Report From NANT Consortium.
  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2021 DuBois SG, Granger MM, Groshen S, Tsao-Wei D, Ji L, Shamirian A, Czarnecki S, Goodarzian F, Berkovich R, Shimada H, Villablanca JG, Vo KT, Pinto N, Mosse YP, Maris JM, Shusterman S, Cohn SL, Goldsmith…
• Association of image-defined risk factors with clinical features, histopathology, and outcomes in neuroblastoma.
  Cancer medicine 2020 Temple WC, Vo KT, Matthay KK, Balliu B, Coleman C, Michlitsch J, Phelps A, Behr S, Zapala MA
• 124I-MIBG PET/CT to Monitor Metastatic Disease in Children with Relapsed Neuroblastoma.
  Journal of nuclear medicine : official publication, Society of Nuclear Medicine 2020 Aboian MS, Huang SY, Hernandez-Pampaloni M, Hawkins RA, VanBrocklin HF, Huh Y, Vo KT, Gustafson WC, Matthay KK, Seo Y
• Precision Medicine in Pediatric Oncology.
  Surgical oncology clinics of North America 2019 Vo KT, Parsons DW, Seibel NL
• Risk Factors for Transplant-Associated Thrombotic Microangiopathy after Autologous Hematopoietic Cell Transplant in High-Risk Neuroblastoma.
  Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation 2019 Tolbert VP, Dvorak CC, Golden C, Vissa M, El-Haj N, Perwad F, Matthay KK, Vo KT
• Technical Note: Simplified and practical pretherapy tumor dosimetry - A feasibility study for 131 I-MIBG therapy of neuroblastoma using 124 I-MIBG PET/CT.
  Medical physics 2019 Seo Y, Huh Y, Huang SY, Hernandez-Pampaloni JM, Hawkins RA, Gustafson WC, Vo KT, Matthay KK
• Detection of circulating tumour DNA is associated with inferior outcomes in Ewing sarcoma and osteosarcoma: a report from the Children's Oncology Group.
  British journal of cancer 2018 Shulman DS, Klega K, Imamovic-Tuco A, Clapp A, Nag A, Thorner AR, Van Allen E, Ha G, Lessnick SL, Gorlick R, Janeway KA, Leavey PJ, Mascarenhas L, London WB, Vo KT, Stegmaier K, Hall D, Krailo MD, …
• Phase 1 study of sirolimus in combination with oral cyclophosphamide and topotecan in children and young adults with relapsed and refractory solid tumors.
  Oncotarget 2017 Vo KT, Karski EE, Nasholm NM, Allen S, Hollinger F, Gustafson WC, Long-Boyle JR, Shiboski S, Matthay KK, DuBois SG
• Incidence and risk factors for secondary malignancy in patients with neuroblastoma after treatment with (131)I-metaiodobenzylguanidine.
  European journal of cancer (Oxford, England : 1990) 2016 Huibregtse KE, Vo KT, DuBois SG, Fetzko S, Neuhaus J, Batra V, Maris JM, Weiss B, Marachelian A, Yanik GA, Matthay KK
• Targeted antiangiogenic agents in combination with cytotoxic chemotherapy in preclinical and clinical studies in sarcoma.
  Clinical sarcoma research 2016 Vo KT, Matthay KK, DuBois SG
• Conditional Survival and Predictors of Late Death in Patients With Ewing Sarcoma.
  Pediatric blood & cancer 2016 Davenport JR, Vo KT, Goldsby R, West DC, DuBois SG
• Impact of Two Measures of Micrometastatic Disease on Clinical Outcomes in Patients with Newly Diagnosed Ewing Sarcoma: A Report from the Children's Oncology Group.
  Clinical cancer research : an official journal of the American Association for Cancer Research 2016 Vo KT, Edwards JV, Epling CL, Sinclair E, Hawkins DS, Grier HE, Janeway KA, Barnette P, McIlvaine E, Krailo MD, Barkauskas DA, Matthay KK, Womer RB, Gorlick RG, Lessnick SL, Mackall CL, DuBois SG
• Identification of patient subgroups with markedly disparate rates of MYCN amplification in neuroblastoma: A report from the International Neuroblastoma Risk Group project.
  Cancer 2015 Thompson D, Vo KT, London WB, Fischer M, Ambros PF, Nakagawara A, Brodeur GM, Matthay KK, DuBois SG
• Clinical, biologic, and prognostic differences on the basis of primary tumor site in neuroblastoma: a report from the international neuroblastoma risk group project.
  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2014 Vo KT, Matthay KK, Neuhaus J, London WB, Hero B, Ambros PF, Nakagawara A, Miniati D, Wheeler K, Pearson AD, Cohn SL, DuBois SG
• Menstrual bleeding patterns and prevalence of bleeding disorders in a multidisciplinary adolescent haematology clinic.
  Haemophilia : the official journal of the World Federation of Hemophilia 2012 Vo KT, Grooms L, Klima J, Holland-Hall C, O'Brien SH
• GLI1 is a central mediator of EWS/FLI1 signaling in Ewing tumors.
  PloS one 2009 Joo J, Christensen L, Warner K, States L, Kang HG, Vo K, Lawlor ER, May WA